| Drug Name |
Sodium phenylbutyrate |
| Drug ID |
BADD_D02048 |
| Description |
A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the γ-globin gene and affects hPPARγ activation. |
| Indications and Usage |
Adjunctive therapy for the management of chronic urea cycle disorders due to deficiencies in carbamylphosphate (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase. it is indicated in all neonatal- onset efficiency presenting within the first 28 days of life. Also indicated in patients with late-onset, presenting after the first month of life with a history of hyperammonemic encephalopathy. |
| Marketing Status |
Prescription |
| ATC Code |
A16AX03 |
| DrugBank ID |
DB06819
|
| KEGG ID |
D05868
|
| MeSH ID |
C075773
|
| PubChem ID |
5258
|
| TTD Drug ID |
D0P2GK
|
| NDC Product Code |
42794-086; 75987-070; 49884-006; 71052-297; 38779-2549; 75987-060; 73309-233; 66326-207; 65571-0006; 66326-210; 66326-504 |
| Synonyms |
4-phenylbutyric acid | 4-phenylbutyric acid, calcium salt | Ammonaps | Buphenyl | 4-phenylbutyrate | 4-phenylbutyric acid, sodium salt | sodium 4-phenylbutanoate | sodium phenylbutyrate | sodium 4-phenylbutyrate |
